Literature DB >> 11761022

Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients.

C Salvarani1, I G Vlachonikolis, D M van der Heijde, G Fornaciari, P Macchioni, M Beltrami, I Olivieri, F Di Gennaro, P Politi, R W Stockbrügger, M G Russel.   

Abstract

BACKGROUND: Musculoskeletal disorders are the most common extra-intestinal manifestation of inflammatory bowel disease (IBD). Wide ranges of prevalence have been reported depending on the criteria used to define spondylarthropathy and on the selection of patients. We aimed to evaluate the prevalence and clinical spectrum of musculoskeletal manifestations in an inception cohort of European IBD patients.
METHODS: From 1 October 1991 to 30 September 1993, 202 IBD patients were diagnosed in three centres of two countries (Italy and The Netherlands) by means of a population-based inception cohort study. Of this group of patients, 160 (79%) were interviewed and examined by a rheumatologist and a gastroenterologist in the period June-September 1996. A total of 139/160 patients had an antero-posterior radiograph of the pelvis, and in 140/160 HLA-B27 was determined.
RESULTS: 53 (33.1%) of the 160 patients had experienced at least one musculoskeletal manifestation, 29 (18.1%) satisfied the European Spondylarthropathy Study Group (ESSG) criteria for spondylarthropathy and 5 (3.1%) satisfied the modified New York criteria for ankylosing spondylitis. However, 23 (14.4%) patients developed one or more spondylarthropathy-related manifestations without fulfilling any of the classification criteria. In patients satisfying ESSG criteria a significantly higher frequency of women (P = 0.03), of ocular and liver involvement (P = 0.01 and P = 0.03, respectively), and use of immunosuppressive drugs (P = 0.02) was observed.
CONCLUSION: Our study shows a high prevalence of musculoskeletal manifestations in an inception cohort of IBD patients. The clinical spectrum is broader than that defined by spondylarthropathy criteria.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11761022     DOI: 10.1080/003655201317097173

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  47 in total

1.  Peripheral arthritis in the course of inflammatory bowel diseases.

Authors:  Ilhami Yüksel; Hilmi Ataseven; Omer Başar; Seyfettin Köklü; Ibrahim Ertuğrul; Aysel Ulker; Ulkü Dağlı; Nurgül Saşmaz
Journal:  Dig Dis Sci       Date:  2010-05-11       Impact factor: 3.199

2.  Review.

Authors:  Kofi Clarke; Jason M Swoger
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-07

3.  Incidence and risk of intestinal and extra-intestinal complications in Medicaid patients with inflammatory bowel disease: a 5-year population-based study.

Authors:  Gaurav Arora; Gurkirpal Singh; Shweta Vadhavkar; Shamita B Shah; Ajitha Mannalithara; Alka Mithal; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2010-04-29       Impact factor: 3.199

Review 4.  Extraintestinal manifestations of inflammatory bowel disease: focus on the musculoskeletal, dermatologic, and ocular manifestations.

Authors:  Paul E Evans; Darrell S Pardi
Journal:  MedGenMed       Date:  2007-03-19

5.  Internet-based data inclusion in a population-based European collaborative follow-up study of inflammatory bowel disease patients: description of methods used and analysis of factors influencing response rates.

Authors:  Frank L Wolters; Gilbert van Zeijl; Jildou Sijbrandij; Frederik Wessels; Colm O'Morain; Charles Limonard; Maurice G Russel; Reinhold W Stockbrugger
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

Review 6.  Extraintestinal manifestations and complications in IBD.

Authors:  Claudia Ott; Jürgen Schölmerich
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-09       Impact factor: 46.802

7.  Nasal Crohn's disease /apheresis.

Authors:  David A Schwartz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-02

Review 8.  Rheumatic manifestations in inflammatory bowel diseases: a link between GI and rheumatology.

Authors:  Rodolfo Perez-Alamino; Hernan Maldonado-Ficco; José A Maldonado-Cocco
Journal:  Clin Rheumatol       Date:  2015-11-17       Impact factor: 2.980

9.  Prevalence of self-reported spondyloarthritis features in a cohort of patients with inflammatory bowel disease.

Authors:  Carmen Stolwijk; Marieke Pierik; Robert Landewé; Ad Masclee; Astrid van Tubergen
Journal:  Can J Gastroenterol       Date:  2013-04       Impact factor: 3.522

Review 10.  Rheumatic manifestations of inflammatory bowel disease.

Authors:  Tatiana Sofía Rodríguez-Reyna; Cynthia Martínez-Reyes; Jesús Kazúo Yamamoto-Furusho
Journal:  World J Gastroenterol       Date:  2009-11-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.